Prognostic value of lymph node to primary tumor standardized uptake value ratio in unresectable esophageal cancer

Po Jui Chen, Wing Keen Yap, Yu Chuan Chang, Yu Chuan Chang, Chen Kan Tseng, Yin Kai Chao, Jason Chia Hsun Hsieh, Jason Chia Hsun Hsieh, Ping Ching Pai, Ching Hsin Lee, Chan Keng Yang, Albert Tsung Ying Ho, Tsung Min Hung*, Tsung Min Hung*

*此作品的通信作者

研究成果: 期刊稿件文章同行評審

13 引文 斯高帕斯(Scopus)

摘要

Background: Unresectable esophageal cancer harbors high mortality despite chemoradiotherapy. Better patient selection for more personalized management may result in better treatment outcomes. We presume the ratio of maximum standardized uptake value (SUV) of metastatic lymph nodes to primary tumor (NTR) in 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography (FDG PET/CT) may provide prognostic information and further stratification of these patients. Methods: The patients with non-metastatic and unresectable esophageal squamous cell carcinoma (SCC) receiving FDG PET/CT staging and treated by chemoradiotherapy were retrospectively reviewed. Receiver operating characteristic (ROC) analysis was performed to determine the optimal cut-off value for NTR. Kaplan-Meier method and Cox regression model were used for survival analyses and multivariable analyses, respectively. Results: From 2010 to 2016, 96 eligible patients were analyzed. The median follow-up time was 10.2 months (range 1.6 to 83.6 months). Using ROC analysis, the best NTR cut-off value was 0.46 for prediction of distant metastasis. The median distant metastasis-free survival (DMFS) was significantly lower in the high-NTR group (9.5 vs. 22.2 months, p = 0.002) and median overall survival (OS) (9.5 vs. 11.6 months, p = 0.013) was also significantly worse. Multivariable analysis revealed that NTR was an independent prognostic factor for DMFS (hazard ratio [HR] 1.81, p = 0.023) and OS (HR 1.77, p = 0.014). Conclusions: High pretreatment NTR predicts worse treatment outcomes and could be an easy-to-use and helpful prognostic factor to provide more personalized treatment for patients with non-metastatic and unresectable esophageal SCC.

原文英語
文章編號545
期刊BMC Cancer
20
發行號1
DOIs
出版狀態已出版 - 10 06 2020

文獻附註

Publisher Copyright:
© 2020 The Author(s).

指紋

深入研究「Prognostic value of lymph node to primary tumor standardized uptake value ratio in unresectable esophageal cancer」主題。共同形成了獨特的指紋。

引用此